U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C13H18ClN3O4S2
Molecular Weight 379.883
Optical Activity ( + )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYCLOPENTHIAZIDE, (+)-

SMILES

NS(=O)(=O)C1=C(Cl)C=C2NC(CC3CCCC3)NS(=O)(=O)C2=C1

InChI

InChIKey=BKYKPTRYDKTTJY-UHFFFAOYSA-N
InChI=1S/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)

HIDE SMILES / InChI

Molecular Formula C13H18ClN3O4S2
Molecular Weight 379.883
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Cyclopenthiazide is a thiazide diuretic. It inhibits the Na+-Cl− symporter in the distal convoluted tubule of the kidney. Cyclopenthiazide is used for the treatment of edema, including that associated with heart failure, and for the treatment of hypertension.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P55017
Gene ID: 6559.0
Gene Symbol: SLC12A3
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NAVIDREX

Approved Use

Navidrex® 0.5mg Tablets are used to treat high blood pressure and some types of heart problems. They are also used to help reduce fluid retention associated with the pre-menstrual syndrome and some kidney or liver diseases.
Primary
NAVIDREX

Approved Use

Navidrex® 0.5mg Tablets are used to treat high blood pressure and some types of heart problems. They are also used to help reduce fluid retention associated with the pre-menstrual syndrome and some kidney or liver diseases.
Primary
NAVIDREX

Approved Use

Navidrex® 0.5mg Tablets are used to treat high blood pressure and some types of heart problems. They are also used to help reduce fluid retention associated with the pre-menstrual syndrome and some kidney or liver diseases.
PubMed

PubMed

TitleDatePubMed
Letter: Paradoxical effect of pindolol.
1975 Jul 19
Effect of long-term diuretic treatment on body-potassium in heart-disease.
1976 Nov 13
Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease.
1985 Sep
Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.
1987 Apr
Is nifedipine a suitable first-line treatment for essential hypertension in general practice?
1987 Nov

Sample Use Guides

In Vivo Use Guide
The usual adult dose is half of one tablet (0.25 mg) , or one whole tablet (0.5 mg) a day, alone or with other medicines.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:19:29 UTC 2023
Edited
by admin
on Sat Dec 16 11:19:29 UTC 2023
Record UNII
T7817XC41U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYCLOPENTHIAZIDE, (+)-
Common Name English
(+)-CYCLOPENTHIAZIDE
Common Name English
2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE, 6-CHLORO-3-(CYCLOPENTYLMETHYL)-3,4-DIHYDRO-, 1,1-DIOXIDE, (+)-
Systematic Name English
Code System Code Type Description
PUBCHEM
2904
Created by admin on Sat Dec 16 11:19:29 UTC 2023 , Edited by admin on Sat Dec 16 11:19:29 UTC 2023
PRIMARY
CAS
96783-05-0
Created by admin on Sat Dec 16 11:19:29 UTC 2023 , Edited by admin on Sat Dec 16 11:19:29 UTC 2023
PRIMARY
FDA UNII
T7817XC41U
Created by admin on Sat Dec 16 11:19:29 UTC 2023 , Edited by admin on Sat Dec 16 11:19:29 UTC 2023
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER